Hexarelin
Dosage Protocol
Hexarelin (Examorelin) is a synthetic hexapeptide GHRP and the most potent growth hormone secretagogue in its class — producing GH release approximately 3× greater than GHRP-6 per dose. Beyond its GH-stimulating properties, Hexarelin demonstrates unique direct cardioprotective effects via CD36 receptor binding on cardiac tissue, making it a compound of active research interest in cardiovascular contexts.
What is Hexarelin?
Hexarelin is a D-2-Nal substituted analog of GHRP-6, with a single amino acid change that dramatically increases potency. It binds GHS-R1a receptors in the pituitary and hypothalamus, producing the strongest GH pulses of any GHRP at equivalent doses. It also binds CD36 receptors on cardiac myocytes, independently of GH, producing documented cardioprotective effects in preclinical models.
The downside of its potency is accelerated receptor desensitization. Hexarelin requires shorter cycles (4–8 weeks maximum) with extended off periods (8+ weeks) to preserve receptor sensitivity. Cortisol and prolactin elevation is moderate — more than Ipamorelin, less than GHRP-6. Its superior cardiac research profile and raw GH output make it a unique compound despite the shorter cycle length.
Dosing Schedule
Parameters documented in published preclinical and clinical research.
| Phase | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| Start | 100 mcg | Once daily (bedtime) | Days 1–7 | Begin conservatively. Potency means lower doses are effective. |
| Working dose | 100–200 mcg | 2× daily | Weeks 2–6 | AM fasted + bedtime. Short cycle — max 8 weeks to limit desensitization. |
| Advanced | 200 mcg | 3× daily | Weeks 2–6 | Doses above 200 mcg add minimal GH but accelerate desensitization. |
| Off cycle | — | — | 8+ weeks | Extended rest is critical to restore receptor sensitivity before next cycle. |
Safety & Side Effects
Academic References
-
[1]
Laron Z, et al. (1995). Growth-enhancing effect of intranasal administration of hexarelin in children with short stature. Acta Endocrinol. 129(3):251–5. PubMed ↗
-
[2]
Muccioli G, et al. (2004). Hexarelin as a cardioprotective agent: structure-activity studies. Endocrinology. 145(1):257–66. PubMed ↗
-
[3]
Broglio F, et al. (1999). Hexarelin, a synthetic GH secretagogue, but not natural GH-releasing peptides, has a direct cardiotropic action. Eur J Endocrinol. 140(5):449–56. PubMed ↗
-
[4]
Torsello A, et al. (1997). Mechanism of action of Hexarelin, a synthetic growth hormone-releasing peptide. Neuroendocrinology. 65(3):205–14. PubMed ↗